SAHA is a well-characterised FDA-approved HDAC inhibitor (HDACi), induces robust NIS mRNA expression in thyroid cells (49, 50), and was shown to improve radioiodide uptake in one of three patients with thyroid cancer in a phase 1 trial (51). The gene discussed is SLC5A5; the disease is thyroid cancer.